You are here
On May 19, the CDC’s Advisory Committee on Immunization Practices (ACIP) published updated dosing recommendations for a meningococcal group B disease (MenB) vaccine in healthy adolescents who are not at increased risk for meningococcal disease.
These recommendations provide guidance on vaccination dosing intervals, for a MenB, vaccine depending on one’s risk of exposure to MenB, which makes it easier for healthcare providers to help protect individuals against this uncommon but potentially fatal disease.
Meningococcal disease is an uncommon, but serious disease that can attack without warning.1,2 It can progress rapidly, and early symptoms are difficult to distinguish from other more common infections—with flu-like symptoms such as headache, nausea and vomiting.3
More specifically, MenB accounts for nearly 50% of all meningococcal cases in 17 to 22 year olds in the United States.4 The disease can lead to death within 24 hours and for survivors may result in life-altering, significant long-term disabilities.3,5,6,7
For more information about MenB, visit MeetMeningitis.com